HR1632-119

What This Bill Does

The Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act creates a new reciprocal marketing approval pathway in the Food, Drug, and Cosmetic Act. A covered product with reciprocal approval is deemed to have an effective U.S. approval, clearance, or premarket notification under the relevant drug, device, or biologics pathway. FDA must grant reciprocal approval when the sponsor requests it and demonstrates that the product is lawfully marketed in a country on the existing section 802(b)(1) list or in the United Kingdom, is not otherwise approved or cleared in the United States, has not had approval or clearance rescinded or withdrawn for safety or effectiveness concerns, and satisfies the bill's conditions. The bill aims to accelerate U.S. access to products accepted by trusted foreign regulators while preserving FDA safety and effectiveness backstop authority.

Who Benefits and How

Patients needing lifesaving treatments benefit if foreign-approved drugs, biologics, or devices reach the U.S. market faster. Medical product sponsors benefit from a request-based pathway that avoids a full ordinary FDA approval process when foreign authorization exists. Device manufacturers benefit because reciprocal approval can substitute for certain U.S. premarket notification or approval pathways. Biologics developers benefit if United Kingdom or listed-country authorization can support U.S. market entry.

Who Bears the Burden and How

FDA must review reciprocal approval requests and police safety or effectiveness exceptions. Domestic medical product competitors may face faster entry from products first authorized abroad. Clinicians must assess products entering through reciprocal approval and explain differences from ordinary FDA review. Patient safety advocates may worry that foreign authorization becomes a shortcut around full U.S. review.

Key Provisions

• Creates reciprocal marketing approval for covered drugs, biologics, and devices.
• Requires lawful marketing authorization in a listed foreign country or the United Kingdom.
• Provides deemed U.S. approval, clearance, or premarket notification for qualifying products.
• Limits eligibility when FDA has rescinded or withdrawn approval or clearance for safety or effectiveness concerns.